Ceftazidime and Status epilepticus - a phase IV clinical study of FDA data

Summary:

Status epilepticus is reported as a side effect among people who take Ceftazidime (ceftazidime), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Vancomycin, and have Osteomyelitis.

The phase IV clinical study analyzes which people have Status epilepticus when taking Ceftazidime. It is created by eHealthMe based on reports of 10,307 people who have side effects when taking Ceftazidime from the FDA, and is updated regularly.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.

What is Status epilepticus?

Status epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure) is found to be associated with 665 drugs and 949 conditions by eHealthMe. Check the latest studies of Status epilepticus.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 29, 2026

10,307 people reported to have side effects when taking Ceftazidime.
Among them, 54 people (0.52%) have Status epilepticus.

Could Ceftazidime cause Status epilepticus?

Among these 54 people:

How long have people been on Ceftazidime when they have Status epilepticus? *

  • < 1 month: 40 %
  • 1 - 6 months: 60 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Status epilepticus when taking Ceftazidime? *

  • female: 48.08 %
  • male: 51.92 %

What is the age of people who have Status epilepticus when taking Ceftazidime? *

  • 0-1: 0.0 %
  • 2-9: 1.85 %
  • 10-19: 11.11 %
  • 20-29: 0.0 %
  • 30-39: 9.26 %
  • 40-49: 7.41 %
  • 50-59: 5.56 %
  • 60+: 64.81 %

What are other drugs people take besides Ceftazidime? *

  1. Vancomycin: 10 people, 18.52%
  2. Augmentin: 7 people, 12.96%
  3. Meropenem: 5 people, 9.26%
  4. Methylprednisolone: 5 people, 9.26%
  5. Ceftriaxone: 4 people, 7.41%
  6. Gentamicin Sulfate: 3 people, 5.56%
  7. Midazolam: 3 people, 5.56%
  8. Ciprofloxacin: 2 people, 3.70%
  9. Daptomycin: 2 people, 3.70%
  10. Metronidazole: 2 people, 3.70%

What are other side effects people have besides Status epilepticus? *

  1. Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system): 14 people, 25.93%
  2. Confusional State: 10 people, 18.52%
  3. Death: 8 people, 14.81%
  4. Myoclonus (a brief, involuntary twitching of a muscle or a group of muscles): 8 people, 14.81%
  5. Blood Creatinine Increased: 7 people, 12.96%
  6. Coma Scale Abnormal: 6 people, 11.11%
  7. Consciousness - Decreased: 6 people, 11.11%
  8. Fever: 5 people, 9.26%
  9. Head Injury: 4 people, 7.41%
  10. Ascites (accumulation of fluid in the abdominal cavity): 4 people, 7.41%

What are the existing conditions these people have? *

  1. Osteomyelitis (infection of bone): 9 people, 16.67%
  2. Pneumonia: 7 people, 12.96%
  3. Pneumonia Pseudomonal (pseudomonas pneumonia is an infection caused by the microbe known as pseudomonas aeruginosa): 6 people, 11.11%
  4. Febrile Neutropenia (fever with reduced white blood cells): 5 people, 9.26%
  5. Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 9.26%
  6. Erythema Multiforme (a type of hypersensitivity reaction): 4 people, 7.41%
  7. Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 4 people, 7.41%
  8. Meningitis (inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges): 3 people, 5.56%
  9. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs): 3 people, 5.56%
  10. Infection Reactivation: 2 people, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftazidime and have Status epilepticus?

- Check whether Status epilepticus is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ceftazidime:

Status epilepticus treatments and more:

How severe was Status epilepticus and when was it recovered:

Expand to all the drugs that have ingredients of ceftazidime:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ceftazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Status epilepticus:

Browse all the conditions that are associated with Status epilepticus:

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on ceftazidime (the active ingredients of Ceftazidime) and Ceftazidime (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: